Loading...

Tony Reid

Title(s)Professor Of Clinical, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    MAGI conference on Clinical Research2013Invited Speaker
    Best of ASCO2013Invited Speaker
    American Society for Clinical Oncology2013Invited Speaker
    AACI annual conference2012Invited Speaker
    MAGI conference on Clinical Research2012Invited Speaker
    American Association for Study of Liver Disease2011Invited Speaker
    American Society of Pathology2010Invited Speaker
    Memorial Sloane Kettering Grand Rounds2010Invited Speaker
    Western Angiographic Society Meeting2010Invited Speaker
    Oncolytic Virus Conference2009Invited Speaker
    Society for Gene Therapy2007Invited Speaker
    13th International Gene Therapy Meeting2005Invited Speaker
    Best of ASCO2002Abstract presentation
    Society of Cardiology and Interventional Radiology2002Young Investigator Award
    10th International Gene Therapy Meeting2002Invited Speaker
    9th International Gene Therapy Meeting2001Invited Speaker
    American Society for Clinical Oncology1998Invited Speaker
    Barry Research1996Fellowship
    Stanford Housestaff1991Research Award
    The Interferon Society1988Young Investigator Award

    Collapse Overview 
    Collapse Overview
    Research Interests
    Professor Tony Reid’s main career goals are to develop novel therapeutic approaches to diagnose, prevent, and treat tumors with gene therapy vectors. He has focused on elucidating the underlying molecular mechanism that causes cancer, focusing primarily in gastrointestinal tumors including colorectal, pancreatic, esophageal and hepatobillary cancers. His research group conducts basic science research to study disease at the molecular level and then facilitates the translation of novel scientific discoveries into practical therapeutic applications to the clinical to benefit patients. His contributions embody the scientific approach of “bench-to-bedside” medicine, promoting greater understanding of cancer and personalized disease therapies. He has a wide range of publications on the uses of new agents for the treatment of tumors and conducts a variety of clinical trials focusing on early phase therapeutics and he also uses gene therapy strategies to enhance the immune response to these tumors. He is the lead investigator and has pioneered the use of adenoviral and vaccine vectors to the treatments of cancer and is always thinking on how he can be instrumental in developing new therapies in the laboratory and how to export them to help those suffering from cancer. His speculative nature has leaded him to explore the scientific underpinnings of cancer and to make new therapeutic options available to patients by developing new clinical trials.

    Clinical Trials: Currently there are many clinical trials on-going at the Moores Cancer Center. Professor Tony Reid’s innovative “thinking out of the box” philosophy of using highly tailored therapies for patients to directly deliver therapeutics specifically to the tumors has led to highly effective outcomes (see section b). One of the pioneering clinical trials for colon cancer patients with mainly liver metastases called the Selective Internal Radiation Therapy (SIRT) Trial using Yttrium-90 (Y-90) Radioactive Microspheres is a Phase II study. This successful clinical trial has been developed to treat patients whose disease has progressed after failing their first-line chemotherapy. Preliminary results so far have shown remarkable differences to patient health having stable disease and progression free survival (PFS) greater than thirty five months.

    b. Past findings and achievements

    i. Study Shows Liver an Excellent Target for Cancer Gene Therapy Using Viral Vectors:
    A Nature Cancer Gene Therapy paper explains the scientific research where the cancer cells in the liver are excellent targets for gene therapy using adenoviral vectors, based on a fundamental new understanding of the differences between cancerous and normal liver cells. The findings showed a new way to treat cancers that have spread to the liver, such as metastatic cancers of the colon and breast.

    ii. Clinical Trial Evaluates Engineered Smallpox Vaccine as Potential Liver Cancer Killer: As part of a multicenter clinical trial, researchers at University of California, San Diego School of Medicine are evaluating Pexa-Vec (JX-594) to slow the progression of hepatocellular carcinoma (HCC) or liver cancer.

    iii. AACI Clinical Research Initiative:

    The Right Drug for the Right Patient: Optimizing Clinical Trials Management


    iv. Spring Sprint Triathlon & Duathlon / MILLIE Award:
    Dr. Reid understands that patients undergoing anti-cancer treatments are doing their “personal best” in the fight against their disease, as are athletes doing their “personal best” as they compete in sporting events such as triathlons. This event will recognize the courage, determination, and strength that cancer patients demonstrate in their daily pursuits to achieve their personal bests.

    c. Current projects and their specific aims
    d. Our exciting new preliminary data proved that when microspheres were administered between first and second line chemotherapy to improve the lives of patients suffering from colorectal cancer. e. Title: A Phase II Study of Yttrium-90 Radioactive Resin Microspheres in the Treatment of Colorectal Adenocarcinoma Metastatic to the Liver After Failure of First-Line Combination Chemotherapy

    Specific aims:
    1) The primary objective is the assessment of progression-free survival of patients with colorectal adenocarcinoma metastatic to the liver after failure of first line combination chemotherapy with Yttrium-90 radioactive resin microspheres.
    2) Secondary objective/outcomes: The secondary objectives are the evaluation of overall survival, tumor response rates, and long-term safety of microspheres in sequence with chemotherapy.

    The Selective Internal Radiation Therapy (SIRT) Trial using Yttrium-90 (Y-90) Radioactive Microspheres inclusion and exclusion criteria can be found by following the hyperlink. We are currently enrolling patients on this trial. For further details please contact us.

    Research 2 -- Erlotinib
    a. Overall focus of the research:
    Title: A Phase I, Open-label, Dose Escalation Study of Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer

    Survival of pancreatic cancer patients remains poor, and treatment with erlotinib remains one of the few agents that have demonstrated increased survival. Alternative dosing schedules for erlotinib should be explored since chronic low dose therapy fails to achieve therapeutically effective concentrations for many patients and leads to increased skin toxicity and may induce acquired resistance without significantly impacting the tumor. Therefore, higher doses given for shorter periods of exposure, similar to the dosing of most chemotherapeutic agents, may achieve more effective therapeutic doses of than chronic low dose therapy and may minimize skin toxicity observed with erlotinib.

    Current findings and achievements
    Preclinical studies performed in the laboratory of the principal investigator Professor Tony Reid support the hypothesis that the currently prescribed erlotinib dose in not optimal for achieving the most effective therapeutic dose range for pancreatic cancer as well as for minimizing skin toxicity. Therefore, our data suggests that acquired resistance can occur rapidly after exposure to erlotinib, and therefore, pulsed high-doses can help to maximize the clinical benefit of the use of erlotinib with having limited adverse effects. We have achieved to complete the first cohort in this clinical trial and we are showing some promising clinical data.
    b. Upcoming research projects
    We have many other projects in the pipeline for colon and pancreatic cancer.
    Please check the following website for further information.

    Collapse Research 
    Collapse Research Activities and Funding
    Novel TNF Chimeric Vector for Treatment of Pancreatic Cancer
    NIH/NCI R21CA122321Aug 1, 2007 - Jul 31, 2009
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19. Semin Oncol. 2020 Jul 07. Oronsky B, Knox S, Cabrales P, Oronsky A, Reid TR. PMID: 32718560.
      View in: PubMed   Mentions:    Fields:    
    2. TGF-beta: a master immune regulator. Expert Opin Ther Targets. 2020 May; 24(5):427-438. Larson C, Oronsky B, Carter CA, Oronsky A, Knox SJ, Sher D, Reid TR. PMID: 32228232.
      View in: PubMed   Mentions: 1     Fields:    
    3. Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patients. Oxf Med Case Reports. 2019 Nov; 2019(11):461-463. Bouvet M, Reid TR, Larson C, Oronsky B, Carter C, Morris JC. PMID: 31844525.
      View in: PubMed   Mentions:
    4. REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer. Future Oncol. 2019 Oct; 15(30):3427-3433. Oronsky B, Reid TR, Larson C, Caroen S, Quinn M, Burbano E, Varner G, Thilagar B, Brown B, Coyle A, Ferry L, Abrouk N, Oronsky A, Scribner CL, Carter CA. PMID: 31509028.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    5. A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs). Oncoimmunology. 2018; 7(9):e1478648. Larson C, Oronsky B, Varner G, Caroen S, Burbano E, Insel E, Hedjran F, Carter CA, Reid TR. PMID: 30228948.
      View in: PubMed   Mentions:
    6. Case Series: Abscopal Benefit of Surgery in 3 Immunotherapy-Treated Patients With Unresectable Cancer. J Investig Med High Impact Case Rep. 2018 Jan-Dec; 6:2324709618786319. Oronsky B, Larson C, Reid TR, Carter CA. PMID: 30083560.
      View in: PubMed   Mentions:    Fields:    
    7. Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells. Oncotarget. 2018 May 04; 9(34):23439-23442. Oronsky B, Reid TR, Oronsky A, Caroen S, Carter CA, Cabrales P. PMID: 29805745.
      View in: PubMed   Mentions: 1     Fields:    
    8. Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review. Neoplasia. 2018 01; 20(1):92-98. Oronsky B, Ma P, Reid TR, Cabrales P, Lybeck M, Oronsky A, Oronsky N, Carter CA. PMID: 29227909.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    9. What's New in SCLC? A Review. Neoplasia. 2017 Oct; 19(10):842-847. Oronsky B, Reid TR, Oronsky A, Carter CA. PMID: 28888101.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    10. No patient left behind: The promise of immune priming with epigenetic agents. Oncoimmunology. 2017; 6(10):e1315486. Carter CA, Oronsky BT, Roswarski J, Oronsky AL, Oronsky N, Scicinski J, Lybeck H, Kim MM, Lybeck M, Reid TR. PMID: 29123948.
      View in: PubMed   Mentions:
    11. Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management. Cancer Chemother Pharmacol. 2017 Nov; 80(5):895-907. Oronsky B, Caroen S, Oronsky A, Dobalian VE, Oronsky N, Lybeck M, Reid TR, Carter CA. PMID: 28730291.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    12. The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury. Expert Rev Hematol. 2017 06; 10(6):575-582. Cabrales P, Caroen S, Oronsky A, Carter C, Trepel J, Summers T, Reid T, Oronsky N, Lybeck M, Oronsky B. PMID: 28448172.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    13. RRx-001 protects against cisplatin-induced toxicities. J Cancer Res Clin Oncol. 2017 Sep; 143(9):1671-1677. Oronsky B, Reid TR, Larson C, Carter CA, Brzezniak CE, Oronsky A, Cabrales P. PMID: 28417195.
      View in: PubMed   Mentions: 6     Fields:    Translation:Animals
    14. RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor. Case Rep Oncol. 2017 Jan-Apr; 10(1):276-280. Brzezniak C, Oronsky B, Trepel J, Summers TA, Cabrales P, Lee MJ, Day R, Jha S, Caroen S, Zeman K, Ferry L, Harmer C, Oronsky N, Lybeck M, Lybeck HE, Brown JF, Reid TR, Carter CA. PMID: 28512410.
      View in: PubMed   Mentions:
    15. RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials. Expert Opin Investig Drugs. 2017 01; 26(1):109-119. Oronsky B, Paulmurugan R, Foygel K, Scicinski J, Knox SJ, Peehl D, Zhao H, Ning S, Cabrales P, Summers TA, Reid TR, Fitch WL, Kim MM, Trepel JB, Lee MJ, Kesari S, Abrouk ND, Day RM, Oronsky A, Ray CM, Carter CA. PMID: 27935336.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    16. A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001. Clin Med Insights Oncol. 2016; 10:105-108. Oronsky B, Caroen S, Zeman K, Quinn M, Brzezniak C, Scicinski J, Cabrales P, Reid TR, Trepel JB, Abrouk ND, Larson C, Oronsky A, Lybeck HE, Day RM, Carter CA. PMID: 27840583.
      View in: PubMed   Mentions:
    17. Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report. Oncol Res Treat. 2016; 39(11):720-723. Brzezniak C, Oronsky B, Scicinski J, Caroen S, Cabrales P, Dean Abrouk N, Kim MM, Brown JF, Reid TR, Larson C, Oronsky A, Day R, Degesys A, Carter CA. PMID: 27855386.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    18. Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents. Biomolecules. 2016 07 04; 6(3). Oronsky B, Scicinski J, Kim MM, Cabrales P, Salacz ME, Carter CA, Oronsky N, Lybeck H, Lybeck M, Larson C, Reid TR, Oronsky A. PMID: 27384589.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    19. A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity? Med Oncol. 2016 Jul; 33(7):63. Cabrales P, Scicinski J, Reid T, Kuypers F, Larkin S, Fens M, Oronsky A, Oronsky B. PMID: 27229330.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    20. Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets. Case Rep Oncol. 2016 May-Aug; 9(2):285-9. Carter CA, Oronsky B, Caroen S, Scicinski J, Degesys A, Cabrales P, Reid TR, Brzezniak C. PMID: 27403127.
      View in: PubMed   Mentions:
    21. Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001. Case Rep Oncol. 2016 Jan-Apr; 9(1):164-70. Carter CA, Schmitz B, Peterson PG, Quinn M, Degesys A, Jenkins J, Oronsky B, Scicinski J, Caroen S, Reid TR, Cabrales P, Brzezniak C. PMID: 27065848.
      View in: PubMed   Mentions:
    22. Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-Distance. Neoplasia. 2015 Sep; 17(9):716-722. Oronsky B, Carter CA, Reid TR, Scicinski J, Oronsky A, Lybeck M, Caroen S, Stirn M, Oronsky N, Langecker P. PMID: 26476079.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    23. Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget. 2015 Aug 21; 6(24):19976-89. Larson C, Oronsky B, Scicinski J, Fanger GR, Stirn M, Oronsky A, Reid TR. PMID: 26280277.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansAnimalsCells
    24. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. Lancet Oncol. 2015 Sep; 16(9):1133-1142. Reid T, Oronsky B, Scicinski J, Scribner CL, Knox SJ, Ning S, Peehl DM, Korn R, Stirn M, Carter CA, Oronsky A, Taylor MJ, Fitch WL, Cabrales P, Kim MM, Burris HA, Lao CD, Abrouk NED, Fanger GR, Infante JR. PMID: 26296952.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    25. Episensitization: Defying Time's Arrow. Front Oncol. 2015; 5:134. Oronsky BT, Oronsky AL, Lybeck M, Oronsky NC, Scicinski JJ, Carter C, Day RM, Rodriguez Orengo JF, Rodriguez-Torres M, Fanger GF, Reid TR. PMID: 26125013.
      View in: PubMed   Mentions:
    26. Phase I study of everolimus, cetuximab and irinotecan as second-line therapy in metastatic colorectal cancer. Anticancer Res. 2015 Mar; 35(3):1567-73. Hecht JR, Reid TR, Garrett CR, Beck JT, Davidson SJ, Mackenzie MJ, Brandt U, Rizvi S, Sharma S. PMID: 25750312.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    27. Encapsulation of adenovirus serotype 5 in anionic lecithin liposomes using a bead-based immunoprecipitation technique enhances transfection efficiency. Biomaterials. 2014 Nov; 35(35):9554-61. Mendez N, Herrera V, Zhang L, Hedjran F, Feuer R, Blair SL, Trogler WC, Reid TR, Kummel AC. PMID: 25154663.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    28. Oncolytic virotherapy. J Vasc Interv Radiol. 2013 Aug; 24(8):1115-22. Sze DY, Reid TR, Rose SC. PMID: 23885911.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    29. Targeting tumors using nanoparticle platforms: a phase I study of a systemically administered gene therapy system. Mol Ther. 2013 May; 21(5):922-3. Larson C, Mendez N, Reid T. PMID: 23636291.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    30. Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study. Cancer. 2013 07 15; 119(14):2555-63. Infante JR, Reid TR, Cohn AL, Edenfield WJ, Cescon TP, Hamm JT, Malik IA, Rado TA, McGee PJ, Richards DA, Tarazi J, Rosbrook B, Kim S, Cartwright TH. PMID: 23605883.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    31. Response to intra-arterial oncolytic virotherapy with the herpes virus NV1020 evaluated by [18F]fluorodeoxyglucose positron emission tomography and computed tomography. Hum Gene Ther. 2012 Jan; 23(1):91-7. Sze DY, Iagaru AH, Gambhir SS, De Haan HA, Reid TR. PMID: 21895536.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    32. Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther. 2010 Sep; 21(9):1119-28. Geevarghese SK, Geller DA, de Haan HA, Hörer M, Knoll AE, Mescheder A, Nemunaitis J, Reid TR, Sze DY, Tanabe KK, Tawfik H. PMID: 20486770.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCellsCTClinical Trials
    33. Resection of hepatic metastasis after 5-fluorouracil and cofactor for colon cancer. Hepatogastroenterology. 2009 May-Jun; 56(91-92):645-9. Costantini CL, Reid TR, Bouvet M. PMID: 19621672.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    34. Fighting fire with fire: effects of oncolytic virotherapy on underlying viral hepatitis in hepatocellular carcinoma. Mol Ther. 2008 Sep; 16(9):1521-3. Reid T. PMID: 18725877.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    35. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer. Future Oncol. 2008 Aug; 4(4):483-500. Trivedi M, Budihardjo I, Loureiro K, Reid TR, Ma JD. PMID: 18684060.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    36. Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther. 2008 Aug; 10(4):371-9. Kumar S, Gao L, Yeagy B, Reid T. PMID: 18683102.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansAnimalsCells
    37. Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib. J Clin Oncol. 2007 Aug 10; 25(23):3544-6. Saylor PJ, Reid TR. PMID: 17687160.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    38. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther. 2005 Aug; 12(8):673-81. Reid TR, Freeman S, Post L, McCormick F, Sze DY. PMID: 15803147.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCellsCTClinical Trials
    39. Dr. Gary J. Becker Young Investigator Award: intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival. J Vasc Interv Radiol. 2003 Mar; 14(3):279-90. Sze DY, Freeman SM, Slonim SM, Samuels SL, Andrews JC, Hicks M, Ahrar K, Gupta S, Reid TR. PMID: 12631632.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    40. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res. 2003 Feb; 9(2):555-61. Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, Kirn DH, Freeman SM. PMID: 12576418.
      View in: PubMed   Mentions: 129     Fields:    Translation:HumansCellsCTClinical Trials
    41. Developments in medical oncology and their implications for interventional radiology. Tech Vasc Interv Radiol. 2002 Sep; 5(3):177-81. Reid TR, Sze DY. PMID: 12524649.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    42. A novel method to control severe upper GI bleeding from metastatic cancer with a hemostatic sealant: the CoStasis surgical hemostat. Gastrointest Endosc. 2002 May; 55(6):735-40. Milkes DE, Friedland S, Lin OS, Reid TR, Soetikno RM. PMID: 11979262.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    Tony's Networks
    Concepts (161)
    Derived automatically from this person's publications.
    _
    Co-Authors (11)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _